All In Biotech

Drug Trial Radar · NCT05737121

Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate the Safety and Effectiveness of VNX001 Compared to Placebo, and the Individual Components of Lidocaine, and Heparin in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Who Have an Episode of Acute Bladder Pain of Moderate to Severe Intensity; The Engage 2024 Study

Last checked: Nov 19, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

May 22, 2023

Primary completion

Jun 2026

Study completion Jun 2026

Sponsor

Lead sponsor
Vaneltix Pharma, Inc.Industry
Sponsor type
Industry
Collaborators
Prevail Infoworks
First posted
Feb 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, multi-center, single-dose, pharmacodynamic study designed to evaluate the efficacy and safety of the combination product (VNX001) versus placebo and its individual components (heparin sodium and lidocaine hydrochloride (HCl)) for the reduction of bladder pain in patients with interstitial cystitis (IC) / bladder pain syndrome (BPS), Who Have an Episode of Acute Bladder Pain of Moderate to Severe Intensity.

Conditions

  • Interstitial Cystitis
  • Bladder Pain Syndrome

Interventions

  • VNX001Drug

    VNX001 (alkalinized lidocaine HCl and heparin sodium)

  • PlaceboDrug

    Inactive placebo for VNX001

  • LidocaineDrug

    Alkalinized lidocaine hydrochloride

  • HeparinDrug

    Alkalinized heparin sodium

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sum of bladder pain intensity differences from baseline to 12 hours post-dose (SPID-12)Time frame: 12 hours

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • IC Study LLC

    Escondido, California · Suspended

  • University of California Los Angeles Center for Women's Pelvic Health

    Los Angeles, California · Completed

  • The Clark Center for Urogynecology

    Newport Beach, California · Recruiting

  • The Continence Center Medical Group, Inc dba Southern California Continence Center

    Newport Beach, California · Completed

  • University of California San Diego Medical Center

    San Diego, California · Recruiting

  • Prestige Medical Group

    Tustin, California · Recruiting

  • United Research Institute

    Hialeah, Florida · Recruiting

  • Florida Urology Partners

    Tampa, Florida · Recruiting

  • Georgia Urology

    Cartersville, Georgia · Recruiting

  • Southern Clinical Research Associates LLC

    Metairie, Louisiana · Recruiting

  • Bay State Clinical Trials

    Watertown, Massachusetts · Recruiting

  • Sheldon Freedman MD LTD

    Las Vegas, Nevada · Recruiting

  • Northwell Health

    Lake Success, New York · Recruiting

  • The Wake Forest Institute of Regenerative Medicine

    Winston-Salem, North Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.